Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

226 to 250 of 316 results

UK's NICE reverses earlier negative decision on Pharmaxis' CF treatment Bronchitol

28-10-2012

Australia's Pharmaxis (ASX: PXS) says that the UK drugs watchdog the National Institute for Health and…

BronchitolEuropePharmaceuticalPharmaxisRare diseasesRegulationRespiratory and Pulmonary

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Bayer presents strong Ph III riociguat data, which met primary endpoint in PAH

23-10-2012

Germany's Bayer (BAYN: DE) HealthCare unit yesterday announced positive data for riociguat from the pivotal…

BayerPharmaceuticalResearchRespiratory and Pulmonaryriociguat

Almirall out-licenses aclidinium to Invida for Australia and New Zealand

12-10-2012

Leading Spanish drugmaker Almirall (ALM: MC) has granted Singapore-based Invida, a member of the Italian…

aclidiniumAlmirallAsia-PacificInvidaLicensingMenariniPharmaceuticalRespiratory and Pulmonary

Merck & Co to initiate Ph III trial with HDM AIT (Mitizax) in North America

11-10-2012

US pharma giant Merck & Co (NYSE: MRK) is planning to advance the clinical development program for the…

Alk-AbelloMerck & CoMitizaxPharmaceuticalResearchRespiratory and Pulmonary

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

US FDA accepts GSK and Theravance NDA for FF/VI; COPD drug filed in Japan

27-09-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say that the New…

Asia-PacificfuroateGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravancevilanterol

SkyePharma partner Kyorin files for Flutiform approval in Japan

26-09-2012

UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma/Mundipharma's Flutiform launched in Germany

23-09-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) last Friday announced the launch of Flutiform,…

EuropeFlutiformMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren

21-09-2012

Spain's largest drugmaker, Almirall (ALM: MC), says that the Danish Health and Medicines Authority has…

AlmirallEklira GenuairEuropeMarkets & MarketingPharmaceuticalPlenadrenRare diseasesRespiratory and PulmonaryViroPharma

Unigene and Tarix report highly increased oral bioavailability of "Peptelligence-engineered" TXA127

20-09-2012

USA-based Unigene Laboratories Laboratories (OTCBB: UGNE) and Tarix Pharmaceuticals yesterday announced…

Cardio-vascularLicensingPharmaceuticalResearchRespiratory and PulmonaryTarix PharmaceuticalsTXA127Unigene Labs

French price regulator authorizes reimbursement of InterMune's Esbriet

12-09-2012

USA-based InterMune (Nasdaq: ITMN) says that French regulator the Comite Economique des Produits de…

EsbrietEuropeInterMunePharmaceuticalPricingRespiratory and Pulmonary

Almirall sets up first direct North America presence

05-09-2012

Almirall (ALM: MC), Spain's largest pharmaceutical company, says it has set up a new affiliate in Canada…

aclidiniumAlmirallMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and Pulmonary

Boehringer reveals new data on olodaterol and tiotropium combo at ERS

04-09-2012

German family-owned drug major Boehringer Ingelheim for the first time presented data from a Phase II…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and PulmonarySpirivatiotropium

Almirall says Eklira Genuair provides meaningful and sustained bronchodilation from the first dose

04-09-2012

Spain's largest drugmaker, Almirall (ALM: MC) yesterday announced positive results for two Phase IIIb…

AlmirallEklira GenuairPharmaceuticalResearchRespiratory and Pulmonary

New data from Novartis on QVA149 and Seebri Breezhaler at ERS

03-09-2012

Further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs…

NovartisPharmaceuticalQVA149ResearchRespiratory and PulmonarySeebri BreezhalerVectura

Sunovion to acquire Elevation Pharma for up to $430 million

03-09-2012

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506) last week…

Dainippon Sumitomo PharmaElevation PharmaceuticalsEP-101Mergers & AcquisitionsPharmaceuticalRespiratory and PulmonarySunovion

FDA warns against use of Pfizer's Revatio in children with PAH

02-09-2012

The US Food and Drug Administration is recommending that Revatio (sildenafil), marketed by US drugs behemoth…

North AmericaPfizerPharmaceuticalRegulationRespiratory and PulmonaryRevatiosildenafil

Novartis set to file QVA149 filing in EU and Japan by end of year

31-08-2012

Swiss drug major Novartis announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium…

NovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonarySeebri BreezhalerVectura

Boehringer's Spiriva has advantages for patients with COPD, says IQWiG

29-08-2012

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD),…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and PulmonarySpiriva

GSK completes LAMA/LABA Ph III program; readies for global filings

28-08-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say they have completed…

GlaxoSmithKlinePharmaceuticalRegulationResearchRespiratory and PulmonaryTheravanceumeclidiniumvilanterol

Flutiform receives UK regulatory approval; solid financials from SkyePharma

24-08-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) yesterday announced that the UK the Medicines…

FinancialFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

226 to 250 of 316 results

Back to top